Express | A warm celebration of project cooperation between Xiyuan Biopharmaceuticals and Sanyou Biopharmaceuticals.
On December 7, 2016, a signing ceremony of project cooperation between Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Shanghai Xiyuan Biopharmaceuticals Co., Ltd. Was held on the second floor of Building 15, No. 188 Xinjunhuan Road, Minhang District, Shanghai. Both parties agreed to the joint commitment of R & D of anti-tumor monoclonal antibody drugs and oncolytic virus drugs.
In attendance of the ceremony are executive
deputy general manager Dr. Kangjian Zhang representing Xiyuan
Biopharmaceuticals, CEO of Sanyou Biopharmaceuticals Dr. Guojun Lang, and
Sanyou Biopharmaceuticals’ main R&D team involved in this project.
Executive Deputy General Manager of
Xiyuan Biopharmaceuticals Dr. Kangjian Zhang and CEO of Sanyou Biopharmaceuticals
Dr. Guojun Lang both talked at the ceremony.
Dr. Zhang shared Xiyuan Biopharmaceuticals’s development process and future
plans; emphasised goals and significance of this project; offered valuable
suggestions for the project implementation. Dr. Lang also shared the development
process and plans; introduced the core technology platform and team members of
Sanyou Biopharmaceuticals, and explained the overall situation of the
After the ceremony, both parties
continued with in-depth communications and discussions on the project
objectives, milestones, technical route, research contents and methods, time
nodes, breakthrough of difficulties, division of labor, use of funds, management
mechanism, risk control, etc, which laid a solid foundation for the smooth
implementation of the project.
After the signing ceremony, both parties conducted in-depth communication and discussion on the project objectives, milestones, technical route, research contents and methods, time nodes, breakthrough of difficulties, division of labor, use of funds, management mechanism, risk control, etc. of this cooperation project, which laid a solid foundation for the smooth implementation of the project.
Both parties believe that this
cooperation marks the beginning of a strategic cooperation between them which
is based on the principles of mutual trust, fairness, justice and win-win cooperation.
Both parties are committed to playing their full respective advantages and
joining their effort in the development of innovative monoclonal antibody drugs
and oncolytic virus drugs and promotion of the R&D of a series of
anti-tumor candidate drugs.
(Left: Dr. Zhang Kangjian; right: Dr. Lang Guojun)
Group photo of all members
Founded in 2005, Shanghai Xiyuan Biopharmaceuticals Co., Ltd. is committed to the R&D and industrialization management of anti-tumor drugs. At present, Xiyuan Biopharmaceuticals has successfully carried out the preclinical study of the anti-cancer drug "Recombinant Human Tumor-targeting Gene -Virus (ZD55-IL-24) Injection". Meanwhile, several of its patented anti-cancer products have entered the preclinical R&D.
Chairman Xinyuan Liu is an academician
of the Chinese Academy of Sciences, Ukrainian Academy of Sciences and the Third
World Academy of Sciences. Nobel Prize
winner Richard J. Roberts is the Chairman of the Academic Committee of China
Research Institute of Biotechnology, founder of the Shanghai Society of
Bioengineering, and founder of Shanghai Huaxin Biotechnology Co., Ltd.